Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
about
Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic LeukemiaAdoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesLymphoma Immunotherapy: Current StatusCD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Cord blood graft engineeringT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectCD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic LeukaemiaAdoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesEngineering cord blood to improve engraftment after cord blood transplant.Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.Cord blood-derived hematopoietic stem/progenitor cells: current challenges in engraftment, infection, and ex vivo expansion.A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytesImproving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodK562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsCellular therapies in acute lymphoblastic leukemiaFunctionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell TransplantationDissecting graft-versus-leukemia from graft-versus-host-disease using novel strategiesAntiviral cell therapy: is this the future?Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 studyIL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.Chimeric antigen receptors (CARs) from bench-to-bedside.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.Novel cord blood transplant therapies.Immunotherapy for EBV-associated malignancies.An overview of the progress on double umbilical cord blood transplantation.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".New strategies in cord blood cells transplantation.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Umbilical cord blood graft engineering: challenges and opportunities.Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients.Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.Advances in umbilical cord blood cell therapy: the present and the future.Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition
P2860
Q26740588-984990FA-2A2A-40E8-A3EF-3A7781237CDEQ26775720-8F37EA26-B9DE-4A3F-BF41-BC13FF4DBF32Q26782902-C7B5DE08-E692-4765-9957-F7AFCAFD7E5AQ26783433-84CEA095-A696-4A19-B823-900155CE1F58Q26822376-DC0A61F1-7475-4C01-9994-7A53304D76CEQ26826830-80C6650D-3729-462D-A2A1-481EE2650E76Q28081600-ADC98726-7212-4999-A5D3-46CAF9D41E4BQ29393780-93686053-E0FD-4055-BA5A-7229D4C8E7F5Q33766995-F281C5C5-3CAA-454A-B0DD-1DE9B8F718CCQ34122292-9284F07E-7134-4B9C-84B4-13EDFD03E4DFQ34557953-E5851CDF-8F75-4C77-8F4C-CCDA5F397F9BQ34986499-15F66CFD-9B67-4101-B9A6-A485E7B202E6Q35285087-C5E4FFD8-BB41-485E-AB5F-613B27403C37Q35522878-5DBD909F-D1A6-474B-88BD-2AD369D7B3B7Q35556061-40F47AD8-5C88-4AA0-AC35-0349F48E9B7DQ35582326-0DD3B213-8E3B-435C-B15A-24EC1B3D49B8Q35812085-5100CC0A-B1FB-47FE-B29D-34664F6FD6ADQ36366557-30ABEBDB-B7F7-46C8-8C34-CF5DAFD8BD98Q36470354-9BB8D465-D725-4BE2-8B68-114D843A6499Q36552098-FEFDA7C2-9971-47F6-B010-0DBCE2D64225Q36578672-6C23EF9B-3BEF-4D24-8B62-47BF7FCDC085Q36819337-5569D4BF-50D4-46BC-A58B-D9F5A0A75146Q36962638-D4F6C0EC-5931-4980-987D-249AE4E152ACQ37263151-EF713F0D-0574-427A-B985-CB39BC6D26B0Q37536195-AACDD40E-03DE-4382-9BFB-A63E999C4C0CQ37587780-33FDC004-20ED-41D2-B740-B3A358097CF3Q37723469-6D5723A7-EAA3-4206-AA46-AC87DB48BE32Q37785538-CC7C2841-07F1-4373-8F79-0FD8EFA217C1Q37800641-1EF412E6-58B6-4908-B5C6-558E38DCC477Q37845178-67B179F0-890E-4CD4-8191-D38B864C1713Q37872506-447124B3-C8DD-4EA6-9A04-B855607C62C2Q37905034-3E814A18-8F83-4461-83C6-769C4F306B75Q37919880-F73E45B5-88FE-4B96-BBB5-9A0230C98D3DQ38099291-A3EE355A-5374-4188-A089-2909798E2E4AQ38289029-0E5BA617-929F-44DE-B8F0-FAD4101DD177Q38514503-72B69CA6-7576-4260-BEBA-9EF461018425Q38586429-94561425-3DCB-426A-A138-5B87B343A692Q38658670-61B2C554-82B6-44F5-A634-E7AC499A2C5BQ38734758-69402096-93FF-4278-A763-CC8622900FEDQ39085608-DF05C15B-BC31-4963-9984-4F48438D9C2F
P2860
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Derivation of human T lymphocy ...... fter stem cell transplantation
@ast
Derivation of human T lymphocy ...... fter stem cell transplantation
@en
type
label
Derivation of human T lymphocy ...... fter stem cell transplantation
@ast
Derivation of human T lymphocy ...... fter stem cell transplantation
@en
prefLabel
Derivation of human T lymphocy ...... fter stem cell transplantation
@ast
Derivation of human T lymphocy ...... fter stem cell transplantation
@en
P2093
P2860
P1433
P1476
Derivation of human T lymphocy ...... fter stem cell transplantation
@en
P2093
Adrian P Gee
Ann M Leen
Barbara Savoldo
Catherine M Bollard
Cliona M Rooney
Elizabeth J Shpall
Gail J Demmler-Harrison
Gianpietro Dotti
Helen E Heslop
P2860
P304
P356
10.1182/BLOOD-2009-09-242263
P407
P577
2010-01-28T00:00:00Z